05:10 PM EDT, 08/12/2024 (MT Newswires) -- Syros Pharmaceuticals ( SYRS ) was plunging 67% in Monday after-hours session after saying it will stop enrolling new patients for a phase 2 trial of tamibarotene for acute myeloid leukemia with RARA gene overexpression after an interim analysis suggested the probability for success was low.

The trial was studying tamibarotene with a combination of venetoclax and azacitidine to treat newly diagnosed, unfit patients with acute myeloid leukemia.

Syros will continue a phase 3 trial evaluating tamibarotene in combination with azacitidine in newly diagnosed patients with higher-risk myelodysplastic syndrome and RARA gene overexpression. Data from that study is expected before the end of the year.

Price: 1.64, Change: -3.37, Percent Change: -67.27